Rv0652-treated DCs induce proliferation of CD4⁺ and CD8⁺ T cells and a Th1 response.

<p>Transgenic OVA-specific CD8⁺ T cells (A-i) and OVA-specific CD4⁺ T cells (B-i) were isolated and stained using CFSE. These cells were then co-cultured for 96 h with untreated DCs, DCs pulsed with OVA h with untreated DCs, DCs pulsed with OVA_257–264, Rv0652 (1 ug/ml)-treated DCs pulsed with OVA_257–264, or LPS (200 ng ng/ml)-treated DCs pulsed with OVA_257–264. T-cell proliferation was assessed using flow cytometry and the percentage of proliferating cells is shown in each panel. Bar graphs show the percentage of OVA-specific CD8⁺ T cells (A-ii) and OVA-specific CD4⁺ T cells (B-ii) from 3 independent experiments. ***<i>P</i><0.001 compared to T cells/OVA pulsed-DCs. (C) IFN-gamma production was measured in each culture supernatant from Fig. 5A and 5B after 24 h of culture by performing an ELISA. Data are the mean and SEM of 3 experiments. ***<i>P</i><0.001 compared to the value from T cell/OVA peptide-pulsed DCs.